Literature DB >> 19035342

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Lucy J Walker, Julia Newton, David E J Jones, Margaret F Bassendine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19035342     DOI： 10.1002/hep.22670

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  13 in total

1.  Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors:  Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 2.  New therapies for primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

3.  Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Authors:  Alanna M K Dubrovsky; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

4.  Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.

Authors:  Manyun Dai; Julin Yang; Minzhu Xie; Jiao Lin; Min Luo; Huiying Hua; Gangming Xu; Hante Lin; Danjun Song; Yuqing Cheng; Bin Guo; Jinshun Zhao; Frank J Gonzalez; Aiming Liu
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

5.  Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis.

Authors:  Xuan Guoyun; Ding Dawei; Liu Ning; Hu Yinan; Yang Fangfang; Tian Siyuan; Sun Hao; Yang Jiaqi; Xu Ang; Guo Guanya; Chen Xi; Shang Yulong; Han Ying
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

Review 6.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

7.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

8.  Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

Authors:  Nisanne S Ghonem; James L Boyer
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

9.  Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

Authors:  Anna Reig; Pilar Sesé; Albert Parés
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

10.  Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.

Authors:  Vinod S Hegade; Amardeep Khanna; Lucy J Walker; Lin-Lee Wong; Jessica K Dyson; David E J Jones
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.